China’s early-stage investor Morningside Venture Capital has led a $40-million Series A investment in gene therapy company Apic Bio, which is developing treatment options for patients with rare genetic diseases.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
